LIPO Lipella Pharma: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Lipella Pharmaceuticals (LIPO) management is betting on the development of targeted drug delivery systems for the therapy of inflammation and urological pathologies. The price action based on the EV/EBITDA metric is . The company strictly adheres to bioethical standards and environmental regulations, reducing harmful emissions in its laboratories. The business relies on an autonomous production cycle, which makes it resilient to global crises and transforms it into a reliable defensive asset.

Lipella Pharmaceuticals' narrow specialization in FDA-protected orphan drugs creates a sustainable market barrier. The EV/EBITDA metric correlates the total enterprise value with operating profit before depreciation and interest, revealing the real value of assets relative to their ability to generate cash flow. By analyzing the historical EV/EBITDA trend of Lipella Pharmaceuticals, an investor can quickly identify leverage risks or margin compression.